Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Growth Hormone Deficiency: full-pipeline trial registry
5 of 17 indexed Growth Hormone Deficiency trials are currently recruiting.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 5 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Growth Hormone Deficiency: 17 US clinical trials tracked, 5 recruiting.
Growth Hormone Deficiency is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Ascendis Pharma Endocrinology Division A/S, running 3 of these trials.
Enrollment posture brief
Registry condition growth-hormone-deficiency
OPEN 5 | RECR 29% | LATE 6 | EARLY 6 | RANK #1004 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Addiction (29% recruiting · 17 trials)
Growth Hormone Deficiency lists 5 open slots (29% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Growth Hormone Deficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Growth Hormone Deficiency is recruiting below its size-band peers.
5 of 17 indexed trials (29.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Growth Hormone Deficiency research.
Ascendis Pharma Endocrinology Division A/S accounts for 3 of 17 trials (17.6%). 13 distinct sponsors appear on at least one study for this condition label.
-
Most Growth Hormone Deficiency trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 17 trials that report a genuine target (sentinel values excluded). 12 of those (70.6%) plan for fewer than 100 participants.
-
Growth Hormone Deficiency research is mostly interventional.
13 interventional and 4 observational studies make up this index (76.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
Chromosome 18 Clinical Research Center
The University of Texas Health Science Center at San Antonio
NCT00227253
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
Ascendis Pharma Endocrinology Division A/S
NCT05820672
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
Ascendis Pharma Endocrinology Division A/S
NCT05775523
Growth Hormone Replacement Therapy for Retried Professional Football Players
Center for Neurological Studies
NCT04121780
Effects of GH and Lirglutide on AgRP
Columbia University
NCT05681299
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S
NCT04615273
Genotropin Study Assessing Use of Injection Pen
Pfizer
NCT00965484
Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency
Massachusetts General Hospital
NCT00182091
VRS-317 in Adult Subjects With Growth Hormone Deficiency
Versartis
NCT01359488
Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers
OPKO Health
NCT02418767
Testosterone and Growth Hormone for Bone Loss in Men
University of Pennsylvania
NCT00080483
Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy
Children's Mercy Hospital Kansas City
NCT00711061
Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia
Children's Hospital Los Angeles
NCT00140413
Growth Hormone and Chromosome 18q- and Abnormal Growth
The University of Texas Health Science Center at San Antonio
NCT00134420
Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
Lumos Pharma
NCT05250063
A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood
Oregon Health and Science University
NCT00212758
Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates
Oregon Health and Science University
NCT00517062
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
| Phase 3 | 3 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Growth Hormone Deficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Growth Hormone Deficiency trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Growth Hormone Deficiency page
17 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Growth Hormone Deficiency trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Ascendis Pharma Endocrinology Division A/S sponsors the most Growth Hormone Deficiency trials on record, review their full trial history before evaluating a specific study. See Ascendis Pharma Endocrinology Division A/S's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Growth Hormone Deficiency condition card totals 17 registered trials; most-linked intervention Nutropin AQ; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.